mean (SD) 7.3 (4.2) a 6, p.52 ,
median (range) 6 ,
median (range) 0.49 (0.23-1.37 ,
3) 38 patients 15.2 (10.8) 34 patients 29) 84 patients 17.4 (12.3) 68 patients 30.6 (12.0) 45 patients 18.0 (13.2) 35 patients 26.9 (13.8) 39 patients 16.6 (11.5) 33 patients - Decline in SDAI, mean (SD) - -15 ,
Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis, Arthritis & Rheumatism, vol.18, issue.1, pp.14-21, 2000. ,
DOI : 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, The Lancet, vol.359, issue.9313, pp.1173-1180, 2002. ,
DOI : 10.1016/S0140-6736(02)08213-2
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.5, pp.670-675, 2007. ,
DOI : 10.1136/ard.2006.062497
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search, Annals of the Rheumatic Diseases, vol.69, issue.4, pp.638-681, 2010. ,
DOI : 10.1136/ard.2009.123976
Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis, Joint Bone Spine, vol.80, issue.1, pp.29-33, 2013. ,
DOI : 10.1016/j.jbspin.2012.02.005
Why do people with rheumatoid arthritis still die prematurely?, Annals of the Rheumatic Diseases, vol.67, issue.Suppl 3, pp.30-34, 2008. ,
DOI : 10.1136/ard.2008.098038
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830861
Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases, Arthritis Research & Therapy, vol.11, issue.3, p.229, 2009. ,
DOI : 10.1186/ar2669
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA), Annals of the Rheumatic Diseases, vol.71, issue.1, pp.62-70, 2014. ,
DOI : 10.1136/annrheumdis-2013-204223
The risk of hospitalized infection in patients with rheumatoid arthritis, J Rheumatol. mars, vol.35, issue.3, pp.387-93, 2008. ,
Predictors of infection in rheumatoid arthritis, Arthritis & Rheumatism, vol.140, issue.9, pp.2294-300, 2002. ,
DOI : 10.1002/art.10529
Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis, Arthritis Care & Research, vol.131, issue.Suppl, pp.36-45, 2016. ,
DOI : 10.1002/acr.22642
Mortality in rheumatoid arthritis: 2008 update, Clin Exp Rheumatol. oct, vol.26, issue.5, pp.35-61, 2008. ,
Mortality in established rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, vol.21, issue.5, pp.871-83, 2007. ,
DOI : 10.1016/j.berh.2007.05.003
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, vol.52, issue.1, pp.53-61, 2013. ,
DOI : 10.1093/rheumatology/kes305
Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative, Annals of the Rheumatic Diseases, vol.74, issue.2, pp.965-73, 2016. ,
DOI : 10.1136/annrheumdis-2016-209233
Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis, Rheumatology International, vol.64, issue.5, pp.445-58, 2015. ,
DOI : 10.1007/s00296-014-3196-7
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative, The Journal of Rheumatology, vol.42, issue.10, pp.1767-80, 2015. ,
DOI : 10.3899/jrheum.141112
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses, Arthritis Research & Therapy, vol.13, issue.4, p.139, 2011. ,
DOI : 10.1136/ard.2009.125526
Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.44, issue.8, pp.1074-81, 2008. ,
DOI : 10.1002/art.23913
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.30, issue.(2), pp.529-564, 2014. ,
DOI : 10.1136/annrheumdis-2013-204575
The Comparative Safety of Tumor Necrosis Factor??Inhibitors in Rheumatoid Arthritis: A??Meta-analysis Update of 44 Trials, The American Journal of Medicine, vol.127, issue.12, pp.1208-1240, 2014. ,
DOI : 10.1016/j.amjmed.2014.06.012
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, vol.69, issue.(Suppl), pp.492-509, 2014. ,
DOI : 10.1136/annrheumdis-2013-204573
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials, Rheumatology, vol.50, issue.3, pp.552-62, 2011. ,
DOI : 10.1093/rheumatology/keq343
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.25-32, 2009. ,
DOI : 10.1136/ard.2007.083188
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry, Arthritis & Rheumatism, vol.39, issue.Suppl 3, pp.2625-2657, 2010. ,
DOI : 10.1002/art.27555
Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry, Annals of the Rheumatic Diseases, vol.68, issue.(Suppl 10), pp.1108-1121, 2016. ,
DOI : 10.1136/annrheumdis-2015-207362
URL : https://hal.archives-ouvertes.fr/hal-01451900
OP0035???Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate), Annals of the Rheumatic Diseases, vol.74, issue.Suppl 2, pp.78-80, 2015. ,
DOI : 10.1136/annrheumdis-2015-eular.3807
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood. 15 janv, vol.83, issue.2, pp.435-480, 1994. ,
The Biology of CD20 and Its Potential as a Target for mAb Therapy, Curr Dir Autoimmun, vol.8, pp.140-74, 2005. ,
DOI : 10.1159/000082102
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study, Blood. 15 sept, vol.92, issue.6, pp.1927-1959, 1998. ,
Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales, Nature Reviews Rheumatology, vol.369, issue.11, pp.665-73, 2013. ,
DOI : 10.1038/nrrheum.2013.134
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis, Rheumatology International, vol.25, issue.Suppl 46, pp.481-485, 2011. ,
DOI : 10.1007/s00296-009-1307-7
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients, Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1894-1901, 2009. ,
DOI : 10.1136/ard.2008.101675
Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry, Arthritis Care & Research, vol.31, issue.4, 2016. ,
DOI : 10.1002/acr.22912
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis, Clinical Pharmacokinetics, vol.62, issue.Suppl 1, pp.1107-1130, 2015. ,
DOI : 10.1007/s40262-015-0296-9
European League against Rheumatism Preliminary Definition of Remission in Rheumatoid Arthritis for Clinical Trials, 3115717. ,
Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants, Arthritis & Rheumatism, vol.61, issue.Suppl III, pp.43-52, 2011. ,
DOI : 10.1002/art.27740
Regulation of the Acute Phase Response by Cytokines, Perspectives in Biology and Medicine, vol.36, issue.4, pp.611-633, 1993. ,
DOI : 10.1353/pbm.1993.0004
Cytokine control of acute phase protein expression, Eur Cytokine Netw. avr, vol.2, issue.2, pp.89-98, 1991. ,
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study, Annals of the Rheumatic Diseases, vol.56, issue.4, pp.694-702, 2015. ,
DOI : 10.1136/annrheumdis-2013-204345
Interleukin-6 in rheumatoid arthritis, Current Opinion in Rheumatology, vol.18, issue.3, pp.277-81, 2006. ,
DOI : 10.1097/01.bor.0000218949.19860.d1
Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis, Arthritis Care & Research, vol.63, issue.Suppl, pp.353-61, 2013. ,
DOI : 10.1002/acr.21812
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents, Annals of the Rheumatic Diseases, vol.70, issue.8, pp.1401-1407, 2011. ,
DOI : 10.1136/ard.2010.146365
The association between serious infection and disease outcome in patients with rheumatoid arthritis, Clinical Rheumatology, vol.71, issue.5, pp.213-221, 2016. ,
DOI : 10.1007/s10067-015-3143-3